Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study

Zhenyu He,Lili Ren,Juntao Yang,Li Guo,Luzhao Feng,Chao Ma,Xia Wang,Zhiwei Leng,Xunliang Tong,Wang Zhou,Geng Wang,Ting Zhang,Yan Guo,Chao Wu,Qing Wang,Manqing Liu,Conghui Wang,Mengmeng Jia,Xuejiao Hu,Ying Wang,Xingxing Zhang,Rong Hu,Jingchuan Zhong,Jin Yang,Juan Dai,Lan Chen,Xiaoqi Zhou,Jianwei Wang,Weizhong Yang,Chen Wang

DOI: https://doi.org/10.1016/s0140-6736(21)00238-5

IF: 202.731

2021-03-01

The Lancet

Abstract:<h2 class="section-title u-h3 u-margin-l-top u-margin-xs-bottom">Summary</h2><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background</h3><p>Wuhan was the epicentre of the COVID-19 outbreak in China. We aimed to determine the seroprevalence and kinetics of anti-SARS-CoV-2 antibodies at population level in Wuhan to inform the development of vaccination strategies.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>In this longitudinal cross-sectional study, we used a multistage, population-stratified, cluster random sampling method to systematically select 100 communities from the 13 districts of Wuhan. Households were systematically selected from each community and all family members were invited to community health-care centres to participate. Eligible individuals were those who had lived in Wuhan for at least 14 days since Dec 1, 2019. All eligible participants who consented to participate completed a standardised electronic questionnaire of demographic and clinical questions and self-reported any symptoms associated with COVID-19 or previous diagnosis of COVID-19. A venous blood sample was taken for immunological testing on April 14–15, 2020. Blood samples were tested for the presence of pan-immunoglobulins, IgM, IgA, and IgG antibodies against SARS-CoV-2 nucleocapsid protein and neutralising antibodies were assessed. We did two successive follow-ups between June 11 and June 13, and between Oct 9 and Dec 5, 2020, at which blood samples were taken.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Findings</h3><p>Of 4600 households randomly selected, 3599 families (78·2%) with 9702 individuals attended the baseline visit. 9542 individuals from 3556 families had sufficient samples for analyses. 532 (5·6%) of 9542 participants were positive for pan-immunoglobulins against SARS-CoV-2, with a baseline adjusted seroprevalence of 6·92% (95% CI 6·41–7·43) in the population. 437 (82·1%) of 532 participants who were positive for pan-immunoglobulins were asymptomatic. 69 (13·0%) of 532 individuals were positive for IgM antibodies, 84 (15·8%) were positive for IgA antibodies, 532 (100%) were positive for IgG antibodies, and 212 (39·8%) were positive for neutralising antibodies at baseline. The proportion of individuals who were positive for pan-immunoglobulins who had neutralising antibodies in April remained stable for the two follow-up visits (162 [44·6%] of 363 in June, 2020, and 187 [41·2%] of 454 in October–December, 2020). On the basis of data from 335 individuals who attended all three follow-up visits and who were positive for pan-immunoglobulins, neutralising antibody levels did not significantly decrease over the study period (median 1/5·6 [IQR 1/2·0 to 1/14·0] at baseline <em>vs</em> 1/5·6 [1/4·0 to 1/11·2] at first follow-up [p=1·0] and 1/6·3 [1/2·0 to 1/12·6] at second follow-up [p=0·29]). However, neutralising antibody titres were lower in asymptomatic individuals than in confirmed cases and symptomatic individuals. Although titres of IgG decreased over time, the proportion of individuals who had IgG antibodies did not decrease substantially (from 30 [100%] of 30 at baseline to 26 [89·7%] of 29 at second follow-up among confirmed cases, 65 [100%] of 65 at baseline to 58 [92·1%] of 63 at second follow-up among symptomatic individuals, and 437 [100%] of 437 at baseline to 329 [90·9%] of 362 at second follow-up among asymptomatic individuals).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Interpretation</h3><p>6·92% of a cross-sectional sample of the population of Wuhan developed antibodies against SARS-CoV-2, with 39·8% of this population seroconverting to have neutralising antibodies. Our durability data on humoral responses indicate that mass vaccination is needed to effect herd protection to prevent the resurgence of the epidemic.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Funding</h3><p>Chinese Academy of Medical Sciences &amp; Peking Union Medical College, National Natural Science Foundation, and Chinese Ministry of Science and Technology.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Translation</h3><p>For the Chinese translation of the abstract see Supplementary Materials section.</p>

medicine, general & internal

What problem does this paper attempt to address?

The paper primarily discusses the seroprevalence of antibodies against the novel coronavirus (SARS-CoV-2) and the persistence of humoral immunity among the population in the Wuhan region of China. The study employed a multi-tiered, population-stratified cluster random sampling method to systematically select residents from 100 communities across 13 districts in Wuhan. On April 14-15, 2020, baseline visits were conducted for participants, during which blood samples were collected to test for pan-immunoglobulins, IgM, IgA, IgG antibodies, and neutralizing antibodies against the SARS-CoV-2 nucleocapsid protein. The study also included two follow-up visits, on June 11-13, 2020, and from October 9 to December 5, 2020, to assess changes in antibody levels.

The study found that among 9,542 participants, 532 individuals (5.6%) tested positive for SARS-CoV-2 pan-immunoglobulins, with an adjusted seroprevalence of 6.92% (95% confidence interval: 6.41-7.43). Of these, 82.1% of antibody-positive individuals were asymptomatic. At baseline, 69 individuals (13.0%) were IgM antibody-positive, 84 individuals (15.8%) were IgA antibody-positive, 532 individuals (100%) were IgG antibody-positive, and 212 individuals (39.8%) were neutralizing antibody-positive. During the follow-up period, the proportion of neutralizing antibody-positive individuals remained stable at 44.6% and 41.2% in the two follow-ups, respectively. For the 335 individuals who participated in all three visits and tested positive for pan-immunoglobulins, there was no significant decline in neutralizing antibody levels throughout the study period.

The results indicate that approximately 6.92% of the population in Wuhan developed antibodies against SARS-CoV-2 after the first wave of the epidemic, with about 40% of antibody-positive individuals developing neutralizing antibodies. The persistence data of the humoral immune response suggest that large-scale vaccination is necessary to achieve herd protection and prevent a resurgence of the epidemic. Additionally, the study found that asymptomatic carriers had lower antibody titers than confirmed cases and symptomatic carriers, and although IgG antibody titers decreased over time, the proportion of individuals with IgG antibodies did not significantly reduce.

The paper emphasizes that most people in Wuhan remained susceptible to SARS-CoV-2 infection after the first wave of the epidemic, indicating that vaccination is crucial for establishing herd immunity. The high proportion of asymptomatic infections suggests that most infections were mild, with symptoms not severe enough to prompt medical care. These seroprevalence data will inform public policy-making in response to the COVID-19 pandemic and aid in vaccine development efforts.